Europe injectable drugs market was valued at $104.8 billion in 2020 and will grow by 9.7% annually over 2020-2030 owing to the increasing prevalence of chronic diseases, rising use of self-administered Injectable formulations, technological advancements in drug development, and growing approvals of new injectable drugs such as COVID-19 vaccines.
Highlighted with 33 tables and 54 figures, this 111-page report “Europe Injectable Drugs Market 2020-2030 by Molecule Type (Small, Large), Drug Class (mAbs, Immunoglobulin, Insulin, Vaccines, Cytokines, Peptide Hormone, Blood Factors), Delivery (Pre-filled Syringe, Infusions, Others), Application (Oncology, Infectious Diseases, Autoimmune, Cardiovascular), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe injectable drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe injectable drugs market in every aspect of the classification from perspectives of Molecule Type, Drug Class, Delivery, Application, Distribution Channel, and Country.
Based on Molecule Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Small Molecule
• Large Molecule
Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Monoclonal Antibodies (mAbs)
• Immunoglobulin
• Insulin
• Vaccines
• Cytokines
• Peptide Hormone
• Blood Factors
• Other Drug Classes
Based on Delivery, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Pre-filled Syringe
• Infusions
• Other Deliveries
Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Oncology
• Infectious Diseases
• Autoimmune Diseases
• Cardiovascular Diseases
• Pain
• Neurology
• Other Applications
Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Molecule Type, Drug Class, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Amgen Inc.
Baxter International Inc.
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co. Inc.
Moderna, Inc.
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of Europe Market by Molecule Type 41
3.1 Market Overview by Molecule Type 41
3.2 Small Molecule 43
3.3 Large Molecule 44
4 Segmentation of Europe Market by Drug Class 45
4.1 Market Overview by Drug Class 45
4.2 Monoclonal Antibodies (mAbs) 47
4.3 Immunoglobulin 48
4.4 Insulin 49
4.5 Vaccines 50
4.6 Cytokines 51
4.7 Peptide Hormone 52
4.8 Blood Factors 53
4.9 Other Drug Classes 54
5 Segmentation of Europe Market by Delivery 55
5.1 Market Overview by Delivery 55
5.2 Pre-filled Syringe 57
5.3 Infusions 58
5.4 Other Deliveries 59
6 Segmentation of Europe Market by Application 60
6.1 Market Overview by Application 60
6.2 Oncology 62
6.3 Infectious Diseases 63
6.4 Autoimmune Diseases 64
6.5 Cardiovascular Diseases 65
6.6 Pain 66
6.7 Neurology 67
6.8 Other Applications 68
7 Segmentation of Europe Market by Distribution Channel 69
7.1 Market Overview by Distribution Channel 69
7.2 Hospital Pharmacy 71
7.3 Retail Pharmacy 72
7.4 E-Commerce 73
8 European Market 2019-2030 by Country 74
8.1 Overview of European Market 74
8.2 Germany 77
8.3 U.K. 79
8.4 France 82
8.5 Spain 84
8.6 Italy 86
8.7 Russia 88
8.8 Rest of European Market 91
9 Competitive Landscape 93
9.1 Overview of Key Vendors 93
9.2 New Product Launch, Partnership, Investment, and M&A 96
9.3 Company Profiles 97
Amgen Inc. 97
Baxter International Inc. 99
Eli Lilly and Company 100
Gilead Sciences Inc. 101
GlaxoSmithKline PLC 102
Johnson & Johnson 103
Merck & Co. Inc. 104
Moderna, Inc. 105
Novartis AG 106
Novo Nordisk AS 107
Pfizer Inc. 108
Sanofi SA 109
Teva Pharmaceuticals Industries Ltd. 110
RELATED REPORTS 111
Key Players (this may not be a complete list and extra companies can be added upon request):
Amgen Inc.
Baxter International Inc.
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co. Inc.
Moderna, Inc.
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
*If Applicable.
